Last reviewed · How we verify

Psychopharmaceuticals

Marie Ociskova · discontinued Small molecule ✓ Verified Jun 2026

Psychopharmaceuticals is a Small molecule drug developed by Marie Ociskova. It is currently in discontinued development.

Psychopharmaceuticals are chemical substances that alter psychological functioning by modulating central nervous system (CNS) activity. They affect the brain, with examples of conditions studied in clinical trials including depression, trauma, epilepsy, and pediatric cancer, and interventions such as professional support and internet-based self-administered psychological programs.

At a glance

Generic namePsychopharmaceuticals
SponsorMarie Ociskova
ModalitySmall molecule
Therapeutic areaOther
Phasediscontinued

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Psychopharmaceuticals

What is Psychopharmaceuticals?

Psychopharmaceuticals is a Small molecule drug developed by Marie Ociskova.

Who makes Psychopharmaceuticals?

Psychopharmaceuticals is developed by Marie Ociskova (see full Marie Ociskova pipeline at /company/marie-ociskova).

What development phase is Psychopharmaceuticals in?

Psychopharmaceuticals is in discontinued.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing